AAAAAA
Results: 1-25/39
Authors:
MOYLE GJ
GAZZARD BG
Citation: Gj. Moyle et Bg. Gazzard, FINDING A ROLE FOR ZALCITABINE IN THE HAART ERA, Antiviral therapy, 3(3), 1998, pp. 125-137
METAANALYSIS OF ANTIRETROVIRAL EFFECTS ON HIV-1 RNA, CD4 CELL COUNT AND PROGRESSION TO AIDS OR DEATH
Authors:
HILL AM
DEMASI R
DAWSON D
Citation: Am. Hill et al., METAANALYSIS OF ANTIRETROVIRAL EFFECTS ON HIV-1 RNA, CD4 CELL COUNT AND PROGRESSION TO AIDS OR DEATH, Antiviral therapy, 3(3), 1998, pp. 139-145
Authors:
DAMATO RM
DAQUILA RT
WEIN LM
Citation: Rm. Damato et al., MANAGEMENT OF ANTIRETROVIRAL THERAPY FOR HIV-INFECTION - MODELING WHEN TO CHANGE THERAPY, Antiviral therapy, 3(3), 1998, pp. 147-158
Authors:
ROTHEN M
BISSET LR
JOLLERJEMELKA HI
GROB P
LUTHY R
OPRAVIL M
Citation: M. Rothen et al., IMPROVEMENT IN IMMUNE FUNCTION DUE TO TREATMENT WITH INDINAVIR DESPITE SEVERE IMMUNE-DEFICIENCY, Antiviral therapy, 3(3), 1998, pp. 159-167
Authors:
OPRAVIL M
HILL AM
DEMASI R
DAWSON D
Citation: M. Opravil et al., PREDICTION OF HIV-1 RNA SUPPRESSION AND ITS DURABILITY DURING TREATMENT WITH ZIDOVUDINE LAMIVUDINE/, Antiviral therapy, 3(3), 1998, pp. 169-176
Authors:
SALOMON H
MONTANER JSG
BELMONTE A
WAINBERG MA
Citation: H. Salomon et al., DIMINISHED HIV-1 SENSITIVITY TO STAVUDINE IN PATIENTS ON PROLONGED THERAPY OCCURS ONLY AT LOW-LEVELS AND CANNOT BE ATTRIBUTED TO ANY SINGLEAMINO-ACID SUBSTITUTION IN REVERSE-TRANSCRIPTASE, Antiviral therapy, 3(3), 1998, pp. 177-182
Authors:
HOLGUIN A
DIETRICH U
IMMELMANN A
SORIANO V
Citation: A. Holguin et al., GENOTYPIC AND PHENOTYPIC RESISTANCE TO STAVUDINE AFTER LONG-TERM MONOTHERAPY, Antiviral therapy, 3(3), 1998, pp. 183-186
Authors:
MACHUCA A
GUTIERREZ M
MUR A
SORIANO V
Citation: A. Machuca et al., QUANTITATIVE P24 ANTIGENEMIA FOR MONITORING RESPONSE TO ANTIRETROVIRAL THERAPY IN HIV-1 GROUP O-INFECTED PATIENTS, Antiviral therapy, 3(3), 1998, pp. 187-189
Authors:
TURRIZIANI O
SIMEONI E
DIANZANI F
ANTONELLI G
Citation: O. Turriziani et al., ANTI-HIV ANTIVIRAL ACTIVITY OF STAVUDINE IN A THYMIDINE KINASE-DEFICIENT CELLULAR-LINE, Antiviral therapy, 3(3), 1998, pp. 191-194
Authors:
ATTIA MA
Citation: Ma. Attia, PREVALENCE OF HEPATITIS-B AND HEPATITIS-C IN EGYPT AND AFRICA, Antiviral therapy, 3, 1998, pp. 1-9
Authors:
SCHINAZI RF
SOMMADOSSI JP
Citation: Rf. Schinazi et Jp. Sommadossi, ADVANCES IN THERAPIES FOR VIRAL-HEPATITIS, Antiviral therapy, 3, 1998, pp. 7-9
Authors:
KOZIEL MJ
Citation: Mj. Koziel, THE IMMUNOPATHOGENESIS OF HBV INFECTION, Antiviral therapy, 3, 1998, pp. 13-24
Authors:
NELSON DR
LAU JYN
Citation: Dr. Nelson et Jyn. Lau, PATHOGENESIS OF CHRONIC HEPATITIS-C VIRUS-INFECTION, Antiviral therapy, 3, 1998, pp. 25-35
Authors:
CASEY JL
Citation: Jl. Casey, HEPATITIS-DELTA VIRUS - MOLECULAR-BIOLOGY, PATHOGENESIS AND IMMUNOLOGY, Antiviral therapy, 3, 1998, pp. 37-42
Authors:
PAWLOTSKY JM
GRETCH DR
Citation: Jm. Pawlotsky et Dr. Gretch, MOLECULAR TOOLS FOR THE TREATMENT OF HEPATITIS-C, Antiviral therapy, 3, 1998, pp. 45-55
Authors:
MORREY JD
KORBA BE
SIDWELL RW
Citation: Jd. Morrey et al., TRANSGENIC MICE AS A CHEMOTHERAPEUTIC MODEL FOR HEPATITIS-B VIRUS-INFECTION, Antiviral therapy, 3, 1998, pp. 59-68
Authors:
BLIGHT KJ
KOLYKHALOV AA
REED KE
VAGAPOV EV
RICE CM
Citation: Kj. Blight et al., MOLECULAR VIROLOGY OF HEPATITIS-C VIRUS - AN UPDATE WITH RESPECT TO POTENTIAL ANTIVIRAL TARGETS, Antiviral therapy, 3, 1998, pp. 71-81
Authors:
LITTLEJOHN M
LOCARNINI S
BARTHOLOMEUSZ A
Citation: M. Littlejohn et al., TARGETS FOR INHIBITION OF HEPATITIS-C VIRUS-REPLICATION, Antiviral therapy, 3, 1998, pp. 83-91
Authors:
YAO N
WEBER PC
Citation: N. Yao et Pc. Weber, HELICASE, A TARGET FOR NOVEL INHIBITORS OF HEPATITIS-C VIRUS, Antiviral therapy, 3, 1998, pp. 93-97
THE HEPATITIS-C VIRUS NS3 PROTEINASE - STRUCTURE AND FUNCTION OF A ZINC-CONTAINING SERINE PROTEINASE
Authors:
DEFRANCESCO R
PESSI A
STEINKUHLER C
Citation: R. Defrancesco et al., THE HEPATITIS-C VIRUS NS3 PROTEINASE - STRUCTURE AND FUNCTION OF A ZINC-CONTAINING SERINE PROTEINASE, Antiviral therapy, 3, 1998, pp. 99-109
Authors:
CHU CK
BOUDINOT FD
PEEK SF
HONG JH
CHOI Y
KORBA BE
GERIN JL
COTE PJ
TENNANT BC
CHENG YC
Citation: Ck. Chu et al., PRECLINICAL INVESTIGATION OF L-FMAU AS AN ANTI-HEPATITIS-B VIRUS AGENT, Antiviral therapy, 3, 1998, pp. 113-121
Authors:
BERENGUER M
WRIGHT TL
Citation: M. Berenguer et Tl. Wright, HEPATITIS-C VIRUS IN THE TRANSPLANT SETTING, Antiviral therapy, 3, 1998, pp. 125-136
Authors:
PONTISSO P
GEROTTO M
BENVEGNU L
CHEMELLO L
ALBERTI A
Citation: P. Pontisso et al., COINFECTION BY HEPATITIS-B VIRUS AND HEPATITIS-C VIRUS, Antiviral therapy, 3, 1998, pp. 137-142
Authors:
IINO S
Citation: S. Iino, RELATIONSHIP BETWEEN INFECTION WITH HEPATITIS-C VIRUS AND HEPATOCELLULAR-CARCINOMA IN JAPAN, Antiviral therapy, 3, 1998, pp. 143-146
Authors:
BRAY M
HUGGINS J
Citation: M. Bray et J. Huggins, ANTIVIRAL THERAPY OF HEMORRHAGIC FEVERS AND ARBOVIRUS INFECTIONS, Antiviral therapy, 3(2), 1998, pp. 53-79